Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant

被引：6

作者：

Alabdulaaly, A

Rifkind, J

Solow, H

Messner, HA

Lipton, JH

机构：

[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M5G 2M9, Canada

[2] Markham Stouffville Hosp, Markham, ON L3P 7P3, Canada

来源：

LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 01期

关键词：

CML; alpha interferon; aplasia; BMT;

D O I：

10.1080/1042819031000139774

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A patient with chronic phase Philadelphia chromosome positive CML, developed severe protracted bone marrow hypoplasia after interferon therapy. This complication did not respond to two courses of immunosuppressive therapy with anti-thymocyte globulin, cyclosporin A and prednisone. The patient continued to be transfusion dependent with persistence of Philadelphia chromosome. Allogeneic BMT restored normal hematopoeisis.

引用

收藏

页码：175 / 177

页数：3

相关论文

共 21 条

[1] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].

ALLAN, NC ;

RICHARDS, SM ;

SHEPHERD, PCA .

LANCET, 1995, 345 (8962) :1392-1397

[2] ANTILYMPHOCYTE GLOBULIN, CYCLOSPORINE, AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH ACQUIRED SEVERE APLASTIC-ANEMIA (SAA) - A PILOT-STUDY OF THE EBMT SAA WORKING PARTY [J].

BACIGALUPO, A ;

BROCCIA, G ;

CORDA, G ;

ARCESE, W ;

CAROTENUTO, M ;

GALLAMINI, A ;

LOCATELLI, F ;

MORI, PG ;

SARACCO, P ;

TODESCHINI, G ;

COSER, P ;

IACOPINO, P ;

VANLINT, MT ;

GLUCKMAN, E .

BLOOD, 1995, 85 (05) :1348-1353

[3] INTERFERON-INDUCED CYTO-TOXICITY AND (2'-5') OLIGO(A) SYNTHETASE-ACTIVITY IN T-CELLS - DIFFERENCES IN RESPONSIVENESS AMONG T-CELLS FROM VARIOUS INDIVIDUALS AND AMONG LYMPHOBLASTOID T-CELL LINES [J].

GAZITT, Y ;

BENBASSAT, H ;

WALLACH, D ;

REVEL, M ;

SCHATTNER, A .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1984, 30 (01) :71-79

[4] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia [J].

Guilhot, F ;

Chastang, C ;

Michallet, M ;

Guerci, A ;

Harousseau, JL ;

Maloisel, F ;

Bouabdallah, R ;

Guyotat, D ;

Cheron, N ;

Nicolini, F ;

Abgrall, JF ;

Tanzer, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :223-229

[5] LEUKOCYTE INTERFERON-INDUCED TUMOR-REGRESSION IN HUMAN METASTATIC BREAST-CANCER, MULTIPLE-MYELOMA, AND MALIGNANT-LYMPHOMA [J].

GUTTERMAN, JU ;

BLUMENSCHEIN, GR ;

ALEXANIAN, R ;

YAP, HY ;

BUZDAR, AU ;

CABANILLAS, F ;

HORTOBAGYI, GN ;

HERSH, EM ;

RASMUSSEN, SL ;

HARMON, M ;

KRAMER, M ;

PESTKA, S .

ANNALS OF INTERNAL MEDICINE, 1980, 93 (03) :399-406

[6] RECOMBINANT LEUKOCYTE-A INTERFERON - PHARMACOKINETICS, SINGLE-DOSE TOLERANCE, AND BIOLOGIC EFFECTS IN CANCER-PATIENTS [J].

GUTTERMAN, JU ;

FINE, S ;

QUESADA, J ;

HORNING, SJ ;

LEVINE, JF ;

ALEXANIAN, R ;

BERNHARDT, L ;

KRAMER, M ;

SPIEGEL, H ;

COLBURN, W ;

TROWN, P ;

MERIGAN, T ;

DZIEWANOWSKI, Z .

ANNALS OF INTERNAL MEDICINE, 1982, 96 (05) :549-556

[7]

INGIMARSSON S, 1980, ACTA MED SCAND, V208, P155

[8] SIDE-EFFECTS OF LONG-TERM TREATMENT WITH HUMAN-LEUKOCYTE INTERFERON [J].

INGIMARSSON, S ;

CANTELL, K ;

STRANDER, H .

JOURNAL OF INFECTIOUS DISEASES, 1979, 140 (04) :560-563

[9] PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY [J].

KANTARJIAN, HM ;

SMITH, TL ;

OBRIEN, S ;

BERAN, M ;

PIERCE, S ;

TALPAZ, M ;

ROBERTSON, L ;

KOLLER, C ;

ESTEY, E ;

KEATING, MJ .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (04) :254-261

[10] INTERFERON-INDUCED APLASIA - EVIDENCE FOR T-CELL-MEDIATED SUPPRESSION OF HEMATOPOIESIS AND RECOVERY AFTER TREATMENT WITH HORSE ANTIHUMAN THYMOCYTE GLOBULIN [J].

MANGAN, KF ;

ZIDAR, B ;

SHADDUCK, RK ;

ZEIGLER, Z ;

WINKELSTEIN, A .

AMERICAN JOURNAL OF HEMATOLOGY, 1985, 19 (04) :401-413